Immune cells engineered to fight lymphoma enter human testing

NCT ID NCT07073833

Recruiting now Disease control Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This early-stage trial tests a new treatment called IBR900, made from natural killer (NK) cells, for people with a type of blood cancer called CD20-positive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The study has two parts: first, finding the safest dose of IBR900 alone, then testing it combined with a standard antibody drug (rituximab). The goal is to see if this cell therapy is safe and shows signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBR900 cell injection (NK cells) and rituximab (CD20 antibody)
What this could lead to: If successful, this could offer a new treatment option for patients with hard-to-treat B-cell lymphoma that has not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 40 participants, so safety and dosing are still being determined. The treatment may not work for everyone and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, China
The First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.